
KMTS Stock Forecast & Price Target
KMTS Analyst Ratings
Bulls say
Kestra Medical Techs is attractive fundamentally because it is still in an early commercial ramp yet delivered F1Q27 sales of $31.0M, up 60% y/y and about $2M above consensus, while FY27 revenue guidance was raised to $141M, implying 48% y/y growth. Its gross margin profile is improving quickly, expanding to 56.5% in F1Q27 from 45.7% a year earlier, marking the 11th consecutive quarter of sequential expansion, and management now targets mid-70s gross margins over time as payor mix and revenue-cycle execution improve. The company also has about $320M of liquidity, roughly 15% U.S. market share, and a differentiated ASSURE platform supported by strong clinical data and broadening coverage, which together underpin confidence in sustained share gains and operating leverage.
Bears say
Kestra Medical Techs is challenged by a fundamentally difficult market where WCD success depends on highly subjective patient selection, uncertain mortality benefit, and compliance that must exceed 22 hours per day, making broad adoption inherently uneven. The 2018 VEST trial enrolled 2,348 patients and failed to meet its primary endpoint, with arrhythmic death of 1.6% versus 2.4% in controls, while adherence fell to a median 18.0 hours per day, reinforcing concerns that real-world effectiveness can be limited by wear-time and overuse in low-risk groups. Although Kestra has captured about 12% US share, its ~7.4x forward P/S multiple implies a roughly 120% premium to the aggregate MedTech multiple, leaving the stock vulnerable if execution or adoption slows.
This aggregate rating is based on analysts' research of Kestra Medical Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
KMTS Analyst Forecast & Price Prediction
Start investing in KMTS
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Kestra Medical Technologies Inc (KMTS) Forecast
KMTS Analyst Forecast & Price Prediction
Start investing in KMTS
Order type
Buy in
Order amount
Est. shares
0 shares